Kali Therapeutics Announces Poster Presentation of KT209, a Novel CD19 x CD20 x CD3 Trispecific Antibody, at the EHA 2026 Annual Congress
SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical data for KT209, its novel trispecific antibody candidate, will be presented...
SAN MATEO, Calif., June 8, 2026 /PRNewswire/ -- Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting and multi-specific therapies, today announced that preclinical data for KT209, its novel trispecific antibody candidate, will be presented...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.